Wolff-Parkinson-White Syndrome: Diagnosis, Risk Stratification, and Catheter Ablation
Executive Summary
Wolff-Parkinson-White (WPW) syndrome is the clinical syndrome of ventricular pre-excitation on the resting 12-lead ECG (short PR <120 ms, delta wave, QRS ≥110-120 ms with secondary ST-T abnormalities) combined with documented arrhythmia symptoms. The substrate is an accessory pathway (AP) - an embryologic remnant of fetal AV connections - that bypasses the AV node and directly connects atrial to ventricular myocardium, allowing rapid conduction without the AV nodal decremental gating that normally protects ventricles from atrial tachyarrhythmias. Pre-excitation prevalence on routine ECG is 0.15-0.25%, but the symptomatic WPW SYNDROME affects approximately one-third of those individuals. Three clinical scenarios drive management: (1) orthodromic atrioventricular reentrant tachycardia (AVRT) - 80-95% of WPW arrhythmias - a narrow QRS regular tachycardia at 150-250 bpm with antegrade conduction down the AV node and retrograde conduction up the AP; (2) antidromic AVRT - rare (5-10%) - a wide QRS regular tachycardia with antegrade conduction down the AP and retrograde via the AV node, mimicking ventricular tachycardia; and (3) pre-excited atrial fibrillation - the LIFE-THREATENING emergency in which AF impulses bypass the AV node and conduct rapidly through the AP, causing irregular wide-complex tachycardia at rates often exceeding 250-300 bpm with degeneration to ventricular fibrillation and sudden cardiac death.
Acute management depends on hemodynamic stability and rhythm: stable orthodromic AVRT responds to vagal maneuvers, adenosine 6 mg IV rapid push, then 12 mg if unsuccessful, or beta-blockers; stable antidromic AVRT or pre-excited AF requires procainamide 20-50 mg/min IV up to 17 mg/kg or ibutilide 1 mg IV over 10 min (NOT AV nodal blockers, which can paradoxically accelerate AP conduction); unstable patients require synchronized cardioversion at 100-200 J biphasic. Critical drug rule: AVOID adenosine, verapamil, diltiazem, beta-blockers, and digoxin in any wide-complex tachycardia where pre-excited AF is possible - these AV nodal blockers can degenerate the rhythm to ventricular fibrillation. Definitive therapy for symptomatic WPW is catheter ablation of the accessory pathway via radiofrequency energy with success rates exceeding 95% and complication rates <2% in experienced centers. Asymptomatic WPW patients require risk stratification with exercise testing and electrophysiology study; high-risk asymptomatic individuals (shortest pre-excited RR ≤250 ms during AF, multiple pathways, septal location) should be offered prophylactic ablation.
S1. Pathophysiology and Accessory Pathway Anatomy
During normal cardiac development, the atria and ventricles are electrically connected only through the AV node and bundle of His. Fetal AV ring myocardium is normally absorbed during the first trimester. When this absorption fails, residual muscular bridges - accessory pathways - persist between atrial and ventricular myocardium across the AV groove. Unlike the AV node, accessory pathways exhibit "all-or-none" conduction without the decremental delay that normally limits ventricular response rate during atrial tachyarrhythmias. The pathway has fast conduction velocity (similar to ventricular myocardium) and short refractory periods, allowing 1:1 conduction at rates often exceeding 300 bpm.
Accessory pathway location is described by the AV groove position relative to standard cardiac orientation. Approximately 50-60% are left-sided free wall (commonly accessed via retrograde aortic or trans-septal approach for ablation), 25-30% are posteroseptal, 15-20% are right-sided free wall, and 5-10% are anteroseptal/midseptal (highest risk for AV block during ablation due to proximity to the compact AV node). Multiple pathways occur in 5-10% of patients, identified by changing delta wave morphology between sinus beats or during EP study mapping.
Pre-Excitation Electrophysiology
During sinus rhythm, the atrial impulse simultaneously enters both the AV node (slow, decremental conduction with AH delay 60-130 ms) and the accessory pathway (fast, non-decremental). Because AP conduction reaches the ventricle FIRST, a portion of ventricular myocardium begins to depolarize before the AV nodal-His-Purkinje wavefront arrives. This early depolarization creates the characteristic delta wave - a slurred upstroke at the start of the QRS - representing slow myocyte-to-myocyte spread from the pathway insertion site before the rapid Purkinje system takes over. As the His-Purkinje wavefront catches up and depolarizes the rest of the ventricle, the QRS continues normally, producing the fusion complex of pre-excitation (delta + normal QRS).
The DEGREE of pre-excitation depends on relative conduction times: rapid AP conduction with slow AV nodal conduction yields large delta waves; conversely, sympathetic stimulation that accelerates AV nodal conduction may MINIMIZE pre-excitation, producing intermittent or "concealed" patterns. "Concealed" accessory pathways (~30% of WPW patients in EP studies) conduct only RETROGRADE (V to A); they do not produce delta waves on resting ECG but still support orthodromic AVRT. "Manifest" pathways conduct antegrade (A to V) producing visible pre-excitation. Both types support orthodromic AVRT, but only manifest pathways produce pre-excited AF and sudden death risk.
S2. ECG Recognition and Pathway Localization
Resting ECG Findings
| Feature | Description |
|---|---|
| Short PR interval | <120 ms (normal 120-200 ms); reflects fast AP conduction bypassing AV nodal delay |
| Delta wave | Slurred initial upstroke of QRS (first 30-50 ms); polarity (positive/negative) helps localize the pathway |
| Wide QRS | ≥110-120 ms in adults due to early ventricular activation via AP plus normal His-Purkinje activation |
| Secondary ST-T abnormalities | ST depression and T wave inversion oppositely directed to delta/QRS; reflects abnormal repolarization, NOT ischemia |
| "WPW patterns" by lead V1 | Type A (positive delta + R wave V1, mimics RBBB) = LEFT-sided pathway; Type B (negative delta + QS in V1) = RIGHT-sided |
Don't Mistake Pre-Excitation for Pathology
The ST-T changes of pre-excitation are commonly misdiagnosed as ischemia, infarction, or LV hypertrophy. Look for the SHORT PR and DELTA WAVE before interpreting Q waves, ST changes, or T inversions. If pre-excitation is intermittent (some beats normal, some pre-excited), suspect a pathway with marginal antegrade conduction (lower sudden death risk). Always compare with prior ECGs.
Three Arrhythmias of WPW
| Arrhythmia | Mechanism | QRS Morphology | Treatment |
|---|---|---|---|
| Orthodromic AVRT (80-95%) | Antegrade AV node → ventricle → retrograde AP → atrium | Narrow QRS, regular, 150-250 bpm; retrograde P wave often visible after QRS in inferior leads | Vagal maneuvers, adenosine, beta-blockers; AV nodal blockers SAFE here |
| Antidromic AVRT (5-10%) | Antegrade AP → ventricle → retrograde AV node → atrium | WIDE QRS (full pre-excitation), regular, 150-250 bpm; mimics VT | Procainamide, ibutilide, cardioversion; AV nodal blockers UNSAFE |
| Pre-excited atrial fibrillation | AF impulses cross AP without AV nodal protection | WIDE, IRREGULARLY IRREGULAR QRS, often >250 bpm; varying morphologies | Procainamide, ibutilide, IMMEDIATE cardioversion if unstable; AV nodal blockers CONTRAINDICATED |
Pathway Localization Algorithms
Several validated 12-lead algorithms (Arruda, Milstein, Fitzpatrick) predict pathway location from delta wave polarity and QRS morphology, useful for pre-procedural planning before EP study. Key principles:
- Lead V1 polarity: Positive delta + R wave dominant = LEFT-sided (Type A); negative delta + QS pattern = RIGHT-sided (Type B)
- Inferior lead delta polarity: Negative delta in II, III, aVF suggests posteroseptal or right-posterior pathway; positive delta in inferior leads suggests anterior/anterolateral pathway
- Lead I delta polarity: Negative delta in I = left lateral/free wall; positive delta in I = right-sided or septal
- QRS axis and transition: Late precordial transition (V4-V5) suggests right-sided; early transition (V1-V2) suggests left-sided
Final localization is determined at electrophysiology study by 3D electroanatomic mapping; pre-procedural algorithms guide initial catheter approach (retrograde aortic vs trans-septal vs right atrial mapping).
S3. Acute Management by Rhythm
The single most important decision in acute WPW management is recognizing pre-excited atrial fibrillation, since standard SVT/AF treatments (adenosine, verapamil, diltiazem, beta-blockers, digoxin) can be FATAL. The mantra: an irregularly irregular WIDE complex tachycardia is pre-excited AF until proven otherwise.
Stable Orthodromic AVRT (Narrow QRS, Regular)
| Step | Therapy | Notes |
|---|---|---|
| 1 | Vagal maneuvers (Valsalva, modified Valsalva, carotid sinus massage) | Modified Valsalva (REVERT trial) terminates 43% vs 17% standard; safe and free |
| 2 | Adenosine 6 mg IV rapid push (cubital vein, large bore, saline flush) → 12 mg if unsuccessful → may repeat 12 mg | Terminates >90% of orthodromic AVRT; warn patient about flushing/chest pressure/sense of impending doom; CAUTION if pre-excited AF cannot be excluded |
| 3 | IV beta-blocker: metoprolol 5 mg IV over 2 min, may repeat × 2 | If adenosine fails or is contraindicated; avoid in any wide-complex tachycardia |
| 4 | IV diltiazem 0.25 mg/kg IV (15-20 mg) over 2 min | Alternative non-DHP CCB if beta-blocker contraindicated; SAFE in narrow-complex orthodromic AVRT |
| 5 | Synchronized cardioversion 50-100 J biphasic if drug-refractory or hemodynamic instability develops | Always have pads on patient before adenosine in case of pre-excited AF degeneration |
Pre-Excited Atrial Fibrillation (Wide QRS, Irregularly Irregular) - EMERGENCY
The AV Nodal Blocker Rule (CRITICAL)
In any WIDE-complex tachycardia where pre-excited AF cannot be excluded, AVOID:
- Adenosine (can shorten AP refractory period)
- Verapamil and diltiazem (block AV node, leaving ALL conduction via the AP)
- Beta-blockers (same mechanism)
- Digoxin (slows AV nodal conduction, accelerates AP)
Blocking the AV node in pre-excited AF eliminates the protective AV nodal filter, forcing 1:1 AP conduction at atrial rates of 300-600/min and risking degeneration to ventricular fibrillation. Multiple cardiac arrests have been reported with verapamil in undiagnosed WPW pre-excited AF.
| Status | Therapy |
|---|---|
| UNSTABLE (hypotension, ischemia, altered mental status, pulmonary edema) | Synchronized cardioversion 200 J biphasic immediately; sedation if time permits |
| STABLE pre-excited AF | First-line: procainamide 20-50 mg/min IV, max 17 mg/kg or until rhythm converts, hypotension, QRS widens >50% baseline, or QT >500 ms; alternative: ibutilide 1 mg IV over 10 min, may repeat × 1 dose if needed (caution with QT and torsades); pre-treat hypomagnesemia |
| If drugs fail or instability develops | Synchronized cardioversion 200 J biphasic |
Antidromic AVRT (Wide QRS, REGULAR)
Treat as wide-complex tachycardia of unknown origin. Procainamide IV is preferred; ibutilide acceptable. Avoid AV nodal blockers since the antegrade limb is the AP. Synchronized cardioversion at 100-200 J for instability or drug failure.
When to Consult Electrophysiology
Refer urgently for: (1) any documented pre-excited AF episode (immediate ablation indication); (2) any sustained antidromic AVRT; (3) syncope or aborted sudden cardiac death; (4) recurrent symptomatic orthodromic AVRT despite medical therapy or patient preference; (5) high-risk occupations (pilots, professional drivers, athletes) regardless of symptoms; (6) all symptomatic WPW patients for shared decision-making about ablation; (7) asymptomatic WPW with high-risk features on exercise testing or non-invasive evaluation.
S4. Catheter Ablation and Long-Term Management
Radiofrequency catheter ablation is the definitive curative therapy for WPW syndrome. Performed under conscious sedation or general anesthesia in an electrophysiology lab, the procedure involves: (1) baseline EP study to confirm AP characteristics (location, antegrade/retrograde refractory periods, multiple pathways); (2) 3D electroanatomic mapping to localize the AP insertion site precisely; (3) RF energy delivery (40-50 W, 60 sec per lesion) to ablate the pathway; (4) post-ablation testing to confirm bidirectional block.
| Outcome / Complication | Rate |
|---|---|
| Acute success (loss of pre-excitation and AVRT non-inducibility) | 95-98% for free wall pathways; 90-95% for septal pathways |
| Long-term recurrence | 3-8% within 1 year (re-ablation success >90%) |
| Vascular complication (femoral hematoma, AV fistula, retroperitoneal bleed) | 1-2% |
| Cardiac tamponade | 0.5-1%; emergency pericardiocentesis available in lab |
| AV block requiring permanent pacemaker | 0.5-1% overall; up to 3-5% for septal/parahisian pathways |
| Stroke (left-sided pathways with retrograde aortic approach) | 0.1-0.5%; periprocedural anticoagulation reduces |
| Procedural mortality | 0.05-0.1% |
Post-Ablation Care
Most patients are discharged same day or next morning. Activity restriction for 5-7 days for vascular access site healing. ECG at 1 week and 1 month confirms loss of pre-excitation. Patients with no recurrence at 6-12 months can be considered cured. Athletes and high-risk occupations may be cleared for unrestricted activity after documented success. Anticoagulation is not routinely needed beyond the periprocedural period unless other indications exist.
Special Considerations
| Population | Management Principle |
|---|---|
| Pediatric WPW (age <5 yr) | Many will lose pre-excitation spontaneously by age 5; defer ablation unless life-threatening arrhythmia or persistent symptoms |
| Pregnancy | Defer elective ablation until postpartum; manage acute arrhythmias with adenosine (orthodromic) or DC cardioversion (pre-excited AF); procainamide acceptable |
| Ebstein anomaly | Strong association with right-sided and multiple APs (~25%); refer to congenital EP specialist |
| HCM with WPW | Consider familial PRKAG2 syndrome (glycogen storage disease mimicking WPW); genetic testing if young, family history |
| Athletes | Symptomatic athletes need ablation before return to competitive sports; asymptomatic athletes need risk stratification per consensus guidelines |
S5. Asymptomatic WPW: Risk Stratification
The annual sudden cardiac death risk in asymptomatic WPW is low (approximately 0.1%/year, lifetime risk 3-4%), but is non-zero and warrants risk assessment. Higher-risk features that warrant prophylactic ablation discussion:
| Risk Stratification Modality | Threshold | Significance |
|---|---|---|
| Loss of pre-excitation during exercise | Sudden, abrupt loss at moderate workload | LOW risk - AP refractory period is long; sudden death risk minimal |
| Loss of pre-excitation with class I antiarrhythmic (procainamide test) | Procainamide IV transiently abolishes delta wave | LOW risk - AP refractory period >250-270 ms |
| Persistent pre-excitation through max exercise | Delta wave maintained at peak HR | INTERMEDIATE risk - refer for EP study |
| Shortest pre-excited RR interval during AF (SPERRI) on EP study | ≤250 ms | HIGH risk - prophylactic ablation strongly indicated |
| AP antegrade effective refractory period (APERP) | ≤240 ms | HIGH risk - prophylactic ablation indicated |
| Multiple accessory pathways | Identified on EP mapping | HIGH risk - increased SCD; ablate all pathways |
| Septal pathway location | Anteroseptal or midseptal | HIGHER risk profile but ablation has higher AV block risk; experienced center |
2015 PACES/HRS Pediatric and 2019 ESC Adult Guidelines
Both consensus statements recommend EP study with risk stratification in asymptomatic WPW patients aged 8 years or older, with prophylactic ablation if high-risk features present. For lower-risk profiles (loss of pre-excitation on exercise, intermittent pre-excitation on Holter), shared decision-making with patient/family preference is acceptable, and many will choose surveillance without ablation. Children <8 years rarely require intervention unless symptomatic.
Pearl: Intermittent Pre-Excitation = Lower Risk
If the resting ECG shows BEAT-TO-BEAT alternation between pre-excited and normal QRS during sinus rhythm, the AP has marginal antegrade conduction with a long refractory period. This dramatically reduces the risk of rapidly conducted pre-excited AF and sudden death. Such patients typically do not require EP study unless symptomatic; reassurance and surveillance are reasonable.
Pitfall: Treating Wide-Complex Tachycardia With AV Nodal Blockers
The default reflex of treating "SVT with aberrancy" with adenosine, verapamil, or beta-blockers is appropriate ONLY when the rhythm is regular and SVT is confidently diagnosed. An IRREGULARLY IRREGULAR wide-complex tachycardia in a young patient should be assumed to be pre-excited AF; AV nodal blockers can degenerate to VF. Use procainamide or cardioversion instead.
Practice Insights: Bedside Notes on WPW
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)The accessory pathway in WPW conducts without the AV node's braking, so anything that blocks the node can accelerate the ventricle, and the single most consequential error clinicians have watched made in real time is giving adenosine to an irregularly irregular wide-complex tachycardia, mistaking it for a regular SVT. The rhythm experienced clinicians most fear in WPW is not the textbook orthodromic AVRT. It is pre-excited AF being silently accelerated toward ventricular fibrillation by a well-intentioned AV nodal blocker.
The Tell Experienced Clinicians Train Every Trainee to See in WPW + AF
Orthodromic AVRT is regular and narrow-complex; pre-excited AF in WPW is irregularly irregular and wide-complex with QRS morphology that varies beat to beat. In practice the very first ECG ruler measurement on any wide-complex tachycardia is RR variability. If the rhythm is irregular and wide, the next action is to call procainamide or ibutilide or set up for synchronized cardioversion — never adenosine, verapamil, diltiazem, beta-blockers, or digoxin. clinicians have seen all five of those drugs given to pre-excited AF in real time over years of practice, with deterioration in three of them. Every time the trainee was certain they were treating a regular SVT.
SPERRI Is the Risk Number Seasoned Clinicians Actually Quote to Patients
Shortest pre-excited RR interval during AF (SPERRI) is the single best published predictor of sudden death in WPW, and it is the number experienced practitioners quote to patients and families when discussing prognosis. SPERRI <250 ms during induced or spontaneous AF defines high-risk; ≥250 ms defines low-risk. They induce AF on EP study with isoproterenol infusion (1–4 mcg/min titrated to atrial pacing capture) in every asymptomatic patient who is a competitive athlete, in a high-consequence occupation (pilot, commercial driver, surgeon), or has a strong family history. The number experienced clinicians report — not whether the pathway exists — drives the ablation decision.
Localization Algorithm at the Bedside
Before EP study seasoned clinicians sketch the delta-wave polarity on a 12-lead because the bedside localization tells them what kind of ablation discussion to set up. Negative delta in V1 with positive delta in I and aVL = left lateral (transaortic or transseptal approach, success ~95%, lowest complication rate). Positive delta in V1 with right axis = right free wall. Negative delta in II and aVF with steep R wave in V1 = posteroseptal (highest recurrence rate, ~10%, risk of AV block in mid-septal locations). Experienced practitioners share this localization with the EP lab before they roster the case so the cohort lab time and the catheter selection are matched to the expected pathway.
Asymptomatic WPW Is Not Always Benign
The default belief that asymptomatic WPW is benign costs patients. In experienced practice every asymptomatic ECG finding gets a Holter, an exercise test (delta-wave loss at higher rates is reassuring), and — in high-consequence populations — invasive EP study with SPERRI. clinicians have ablated truly asymptomatic patients with SPERRI 200–230 ms; followed others with SPERRI >270 ms. The question is not "do you have symptoms" — it is "what does your accessory pathway do under stress."
Illustrative Scenario: Sprint Syncope That Was Pre-Excited AF, Not Vasovagal
A man in his early 20s, competitive collegiate sprinter, presented after his second syncopal episode at peak exercise during track training. Resting ECG showed PR 100 ms with classic delta wave, negative delta in V1, positive in I and aVL — left lateral pathway. Treadmill exercise testing reproduced palpitations at 180 bpm; the rhythm strip showed irregularly irregular wide-complex tachycardia with QRS varying from 130 to 200 ms — pre-excited AF, not "exercise-induced SVT" as the prior workup had labeled it. EP study with isoproterenol induced sustained AF; SPERRI measured 220 ms — high-risk. Radiofrequency ablation of the left lateral pathway via transseptal approach achieved complete loss of pre-excitation acutely; at 6-month follow-up Holter and exercise testing were clean, and he was cleared to return to competitive sport with annual cardiology follow-up.
Takeaway: any syncope at peak exertion in a young patient with delta wave on ECG is pre-excited AF until proven otherwise. The risk is not the AVRT they reported in clinic; it is the AF they have not yet documented. Exercise-test reproduction plus EP-study SPERRI measurement is the standard, not a referral courtesy.
Protocol Adjustments Experienced Clinicians Use Beyond the Standard Guideline
- Irregularly irregular + wide-complex = procainamide / ibutilide / DC cardioversion ONLY — never adenosine, verapamil, diltiazem, beta-blockers, or digoxin. The first ruler measurement on any wide tachycardia is RR variability; if irregular, switch off AV-nodal-blocker reflexes immediately.
- SPERRI measurement on EP study, not just pathway documentation — induce AF with isoproterenol 1–4 mcg/min titrated to atrial capture; report the shortest pre-excited RR interval. SPERRI <250 ms = high-risk, ablate; ≥250 ms = low-risk, may follow.
- Bedside delta-wave localization on 12-lead before EP referral — share localization with EP lab so catheter selection and lab time match expected pathway. Left lateral via transseptal; right free wall via femoral venous; posteroseptal needs septal access with AV-node mapping for block risk.
- Asymptomatic WPW gets full workup in high-consequence populations — competitive athletes, pilots, commercial drivers, surgeons, strong family history. Exercise test + Holter + EP study with SPERRI. The number, not the symptom report, decides ablation.
S6. Pearls, Pitfalls, and FAQ
Pearl: Place Pads Before Adenosine in WPW
Adenosine occasionally precipitates atrial fibrillation in WPW patients (rate ~1-15%); if AF develops in a patient with manifest pre-excitation, the resulting pre-excited AF can degenerate rapidly. Always have defibrillator pads attached to the patient and the device in synchronized mode before administering adenosine in any patient with known or suspected WPW.
Pitfall: Ablation in Pediatric Patients Too Early
Pre-excitation is detected on ECG in many newborns and toddlers, but a substantial fraction lose the pathway spontaneously by age 5-7 years as the AP fibroses. Routine ablation in young children carries higher procedural risk per body weight (vascular access, radiation, AV block at smaller AV nodes) without a corresponding survival benefit. Defer ablation in <8-year-olds unless life-threatening arrhythmia is documented or ongoing symptoms warrant.
Pearl: PRKAG2 Mimics WPW + HCM
PRKAG2 syndrome is an autosomal dominant glycogen storage disease that produces a phenotype of pre-excitation PLUS left ventricular hypertrophy in young patients. Genetic testing is warranted in WPW patients who also have unexplained LVH, family history of HCM, or progressive conduction disease. Management includes ablation of the AP and HCM-style assessment for SCD risk.
Pitfall: Mistaking Antidromic AVRT for Ventricular Tachycardia
Antidromic AVRT presents as wide-complex regular tachycardia in a young patient, often without structural heart disease. While the rhythm is "supraventricular" by mechanism, it conducts antegrade through the AP to the ventricle, producing a fully pre-excited QRS that resembles VT. Treatment with amiodarone is acceptable and safe; avoid AV nodal blockers. Procainamide is preferred for stable patients. Cardioversion is the default for instability regardless of mechanism.
FAQ
- Brugada Syndrome: ECG Pattern Recognition, Risk Stratification, and ICD Decision-Making
- Wolff-Parkinson-White Syndrome: Diagnosis and Management
- Long QT Syndrome: Genotype-Specific Diagnosis, Risk Stratification, and Therapy
- Hypertrophic Cardiomyopathy: Diagnosis, Risk Stratification, and Treatment
- Hypertension — Diagnosis, Risk Stratification, and Pharmacotherapy
- Ventricular Tachycardia: ECG Diagnosis, Acute Termination, ICD Indications, and Catheter Ablation Strategy